Bio Pharma Dive
MARCH 3, 2022
Biogen confirmed that some of its U.S. employees have been informed their roles are being eliminated. It's unclear, though, the magnitude of the layoffs or which departments are most affected.
World of DTC Marketing
MARCH 3, 2022
Press Ganey recently asked1 1,000+ healthcare consumers about their digital behaviors, but unfortunately, their findings mean little to emarketers working within the industry. They are somewhat embarrassing. So let’s look at some of the top insights from the report, along with my snide comments: Consumers turn to pharma sites for reliable information: In the age of empowered consumers, access to reliable healthcare information has never been more demand.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 3, 2022
As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.
BioPharma Reporter
MARCH 3, 2022
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
MARCH 3, 2022
While a stock market slide has made IPOs difficult for young biotech companies, venture capital firms like Atlas are still reloading with new cash to create and invest in new drugmakers.
XTalks
MARCH 3, 2022
In the perfect food industry merger and acquisition (M&A) deal, both parties come out ahead. Last year saw several examples of both buyers and sellers in the food industry walking away with something to position them for more stable, sustainable growth. But which countries had the most food industry M&A deals in 2021? US Leads Food Industry M&A Deals.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
MARCH 3, 2022
Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 da
BioPharma Reporter
MARCH 3, 2022
WuXi STA says its drug product facility in Wuxi City, China has successfully passed its first pre-approval inspection (PAI) and received the GMP compliance certificate from the European Medicines Agency (EMA).
XTalks
MARCH 3, 2022
Food allergies are becoming more and more common, but that doesn’t mean those with allergies can’t enjoy a sweet treat. In this episode of the Xtalks Food Podcast, Sydney talks about Partake Foods, an allergen-friendly, better-for-you snack brand that offers cookies, baking mixes and other products in which everyone can partake. However, the brand sells more than just sweet treats.
Pharma Times
MARCH 3, 2022
The phase 3 MELODY study reveals that nirsevimab vaccine reduces lower respiratory tract infections
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
MARCH 3, 2022
DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the combined offering.
Pharma Times
MARCH 3, 2022
NICE document recommends Amgen’s Lumykras (sotorasib) to treat non-small-cell lung cancer
Scienmag
MARCH 3, 2022
These ancient creatures can squeeze through the tiniest cracks, fit snugly into tight spaces and survive in harsh environments: There aren’t many spaces that are off-limits to an insect. Credit: The Shankar Research Group These ancient creatures can squeeze through the tiniest cracks, fit snugly into tight spaces and survive in harsh environments: There aren’t […].
BioPharma Reporter
MARCH 3, 2022
mRNA pioneer Moderna will establish an Enterprise Solutions Hub in Atlanta: which will host finance, human resources, procurement and digital functions.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Scienmag
MARCH 3, 2022
Examining the spines of Neandertals, an extinct human relative, may explain back-related ailments experienced by humans today, a team of anthropologists has concluded in a new comparative study. Credit: Image courtesy of Scott Williams, NYU’s Department of Anthropology. Examining the spines of Neandertals, an extinct human relative, may explain back-related ailments experienced by humans today, […].
BioPharma Reporter
MARCH 3, 2022
IDT Biologika and Exothera S.A. are working together to develop a large-scale manufacturing process for viral vector-based vaccines.
Scienmag
MARCH 3, 2022
A new U of T Scarborough study finds that showing COVID-19 data in a certain way can influence how seriously people view the pandemic, which in turn can impact their behaviour. The study looked at two commonly used types of data: stock (the total case counts since the pandemic started) and flow (the number of […].
BioPharma Reporter
MARCH 3, 2022
UK headquartered Touchlight has agreed a development and manufacturing pipeline agreement with Swiss company, Versameb.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
MARCH 3, 2022
Relatively small, but fearsome-looking stegosaur measured about 2.8 metres (9 feet) from nose to tail—but scientists can’t tell whether the remains are those of an adult or juvenile. Credit: Credit Banana Art Studio Relatively small, but fearsome-looking stegosaur measured about 2.8 metres (9 feet) from nose to tail—but scientists can’t tell whether the remains are […].
pharmaphorum
MARCH 3, 2022
Digital transformation is taking root in every major industry, and healthcare and life sciences are no exception. In fact, digital technology may prove to be more transformative in the healthcare sphere than in other industries as it forces us to rethink core concepts like episodes of care and small molecules in favour of emerging models and tools like ongoing virtual care, digital medicines and therapeutics.
Scienmag
MARCH 3, 2022
Just as electrons flow through an electrical conductor, magnetic excitations can travel through certain materials. Such excitations, known in physics as “magnons” in analogy to the electron, could transport information much more easily than electrical conductors. An international research team has now made an important discovery on the road to such components, which could be […].
The Pharma Data
MARCH 3, 2022
Use of the drug verapamil to treat Type 1 diabetes continues to show benefits lasting at least two years, researchers report in the journal Nature Communications. Patients taking the oral blood pressure medication not only required less daily insulin two years after first diagnosis of the disease, but also showed evidence of surprising immunomodulatory benefits.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
MARCH 3, 2022
Imagine Bach’s “Cello Suite No. 1” played on a strand of DNA. Credit: The Beckman Institute for Advanced Science and Technology at the University of Illinois Urbana-Champaign. Imagine Bach’s “Cello Suite No. 1” played on a strand of DNA. This scenario is not as impossible as it seems. Too small to withstand a rhythmic strum […].
Drug Patent Watch
MARCH 3, 2022
Annual Drug Patent Expirations for ZYNRELEF+KIT Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Heron Theraps drug ZYNRELEF KIT appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
MARCH 3, 2022
High-fidelity touch has the potential to significantly expand the scope of what we expect from computing devices, making new remote sensory experiences possible. The research on these advancements, led by a pair of researchers from the J. Mike Walker ’66 Department of Mechanical Engineering at Texas A&M University, could help touchscreens simulate virtual shapes.
Drug Patent Watch
MARCH 3, 2022
Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
MARCH 3, 2022
In a Policy Forum, Li Tang argues that China’s science funding system needs to play a larger role in curbing scientific misconduct and in improving Chinese research integrity. The Chinese science grant system, which is largely subsidized by government funding, plays an important role in supporting a rapidly growing research and development enterprise well situated […].
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA.
Scienmag
MARCH 3, 2022
They say a picture can convey a thousand words, and researchers have found that using medical imaging technologies that can visualize health may discourage risk-related behaviors more than non-visual information. The meta-analysis, publishing March 3rd in the open access journal PLOS Medicine, finds that when individuals undergo an imaging procedure and are shown visual personalized […].
pharmaphorum
MARCH 3, 2022
March 3, 2022, London, UK — Fishawack Health (FH), a leading commercialization partner for biopharmaceutical, medical technology, and wellness companies, today welcomes the US-based health economics and outcomes research (HEOR) consultancy Policy Analysis Inc. (PAI) as part of its expanding Value, Evidence, and Access (VEA) capability. With the addition of PAI, FH now has one of the largest and fastest-growing teams dedicated to value, evidence, and access, all of which are critical to the comme
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
291 
Let's personalize your content